Lysosomal Ferroptosis: A Novel Lipid Degrader Approach to Cancer Therapy

Introduction

Ferroptosis is a regulated, iron-dependent form of cell death driven by the unchecked peroxidation of membrane lipids. Over the past decade, it has emerged as a critical mechanism in cancer biology, particularly in the context of therapy-resistant tumors. A recent study, “Activation of lysosomal iron triggers ferroptosis in cancer” by Cañeque et al. (2025), presents a significant advancement in this field by identifying lysosomes as the subcellular site where ferroptosis is initiated. The study introduces a novel chemical strategy to exploit this vulnerability using a small molecule, fentomycin-1 (Fento-1), which selectively activates lysosomal iron to induce ferroptosis in iron-rich cancer cells. This essay outlines the mechanistic underpinnings of ferroptosis, the central role of lysosomal iron in its initiation, and the therapeutic implications of targeting this pathway in refractory cancers.

Mechanism and Biological Role of Ferroptosis

Ferroptosis is distinct from apoptosis and necrosis both in morphology and biochemistry. It is characterized by the accumulation of lipid hydroperoxides, particularly in polyunsaturated phospholipids, which compromise membrane integrity and ultimately cause cell death. This oxidative process is fueled by iron-catalyzed Fenton reactions, in which ferrous iron (Fe²⁺) reacts with hydrogen peroxide to generate highly reactive hydroxyl radicals. These radicals initiate and propagate lipid peroxidation chains that are lethal to the cell.

Several molecular players orchestrate ferroptosis. Glutathione peroxidase 4 (GPX4) is a central regulator that detoxifies lipid peroxides; its inhibition, either pharmacologically by RSL3 or via glutathione (GSH) depletion, is sufficient to induce ferroptosis. Another critical component is System Xc⁻, a cystine/glutamate antiporter necessary for GSH synthesis. Inhibitors like erastin block this transporter, further lowering the cellular antioxidant capacity. Iron metabolism also plays a pivotal role, elevated intracellular iron promotes ferroptosis, while iron chelators such as deferoxamine provide protection.

Therapeutically, ferroptosis has been shown to selectively eliminate cancer cell populations that are poorly responsive to standard treatments, such as drug-tolerant persister (DTP) cells and mesenchymal-like cancer cells with elevated iron uptake. Conversely, inhibiting ferroptosis is being investigated in diseases marked by excessive lipid peroxidation, including neurodegenerative disorders and ischemic injuries.

Lysosomal Iron as a Ferroptosis Trigger

Cañeque et al. reveal that lysosomes are not passive participants but active initiators of ferroptosis. They show that the ferroptosis inhibitor liproxstatin-1 (Lip-1) accumulates specifically in lysosomes, where it binds redox-active iron and neutralizes its ability to catalyze lipid peroxidation. On the other hand, the GPX4 inhibitor RSL3 triggers the oxidation of lysosomal lipids before this oxidative cascade spreads to other compartments such as the endoplasmic reticulum.

Lysosomes provide an ideal environment for Fenton chemistry due to their acidity and high concentrations of iron and hydrogen peroxide. CD44-high cancer cells, which are enriched for iron through endocytic uptake, are particularly vulnerable to this form of cell death. To exploit this vulnerability, the researchers developed Fento-1, a bifunctional molecule that combines the membrane-localizing properties of marmycin with an iron-activating Chen–White ligand. Upon endocytosis, Fento-1 accumulates in lysosomes, where it activates redox cycling of iron, triggering the oxidative degradation of phospholipids and initiating ferroptosis in iron-rich tumor cells.

Therapeutic Potential and In Vivo Efficacy

This lysosome-targeted approach holds considerable therapeutic promise. Fento-1 effectively eliminates CD44-high DTP cells derived from sarcoma and pancreatic ductal adenocarcinoma (PDAC), two cancer types known for their resistance to conventional therapies. Interestingly, prolonged exposure to sublethal doses of Fento-1 leads to the emergence of a ferroptosis-tolerant state, characterized by reduced mesenchymal markers and upregulation of ferroptosis suppressors such as GPX4 and FSP1. This adaptation underscores the potential benefit of combining Fento-1 with agents that target resistance mechanisms.

In vivo studies further validate the efficacy of Fento-1. In a mouse model of metastatic breast cancer, intralymphatic administration of Fento-1 significantly suppressed tumor growth and reduced the CD44^high tumor cell population, all without significant toxicity to normal tissues. The molecule preferentially accumulates in lysosomes of iron-rich cancer cells, sparing healthy cells with lower iron content. Moreover, Fento-1 synergized with doxorubicin to eradicate DTP clones, supporting its role in combination therapies. Beyond oncology, the targeted activation of lysosomal iron could be relevant to other iron-dependent diseases such as neurodegeneration and microbial infections, where redox imbalance is a key pathogenic factor.

Conclusion

The findings by Cañeque et al. establish lysosomal iron as a critical regulator of ferroptosis and a viable therapeutic target in cancer. By illuminating the subcellular dynamics of lipid peroxidation and designing Fento-1 as a precision ferroptosis inducer, the study lays the foundation for a new class of targeted therapies that exploit metabolic vulnerabilities in drug-resistant tumors. Future directions should focus on overcoming adaptive resistance through rational combination strategies and extending this approach to other iron-driven pathologies.

Reference

Cañeque, T., Baron, L., Müller, S. et al. Activation of lysosomal iron triggers ferroptosis in cancer. Nature (2025). https://doi.org/10.1038/s41586-025-08974-4

 

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1.  Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217
2. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. bioRxiv 2025.04.15.648836v1 https://www.biorxiv.org/content/10.1101/2025.04.15.648836v1
3.  American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity  Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.

 

 

Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories

 

Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)

 

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)